We would like to thank Dr. Mahmoud Abdelnabi et al. for their valuable comments but according to our opinion, there is confusion about our study design. With regard to the remarks of Dr. Mahmoud Abdelnabi, it should be clear that: 1. The main aim of the study was to determine the prevalence of metabolic syndrome (MS) in patients under 46 years of age who presented with ST elevation myocardial infarction and underwent primary percutaneous coronary intervention and especially this study did not focus on the morphology of coronary lesions 2. The limitations of our study that we mentioned in the limitation part do not affect the prevalence of MS 3. Over the last two decades, various organizations have proposed different definitions, using varying terminologies about MS. There are not just the International Diabetes Federation, the American Heart Association, and the World Health Organization (WHO) but also The European Group for Study of Insulin Resistance proposed a modification of the WHO definition 4. Despite the large number of controversies regarding the nomenclature to be used, this conglomeration of various metabolic abnormalities in NCEP-ATP III criteria has been widely accepted as a screening tool for identifying subjects at high risk of cardiovascular disease and the aim of our study was not to compare these different definitions.
